BusinessMinerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in SchizophreniaBy Nasdaq OMXDec 19, 2017, 1:01 PM UTC
BusinessSchizophrenia Relapse Reduction Disease Management Program – New Resources Released By Frameworks In Health & QualityBy Nasdaq OMXSep 30, 2017, 2:02 PM UTC
BusinessMinerva Neurosciences to Host R&D Day Focused on Unmet Needs and Emerging Treatment Strategies in SchizophreniaBy Nasdaq OMXFeb 21, 2017, 1:30 PM UTC
BusinessAdditional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia Underscore Benefit in Multiple Measurements of Cognitive FunctionBy Nasdaq OMXJan 20, 2017, 1:30 PM UTC
BusinessMinerva Neurosciences Announces Positive Data From Six-Month Extension of Phase IIb Trial of MIN-101 Monotherapy in SchizophreniaBy Nasdaq OMXOct 26, 2016, 12:30 PM UTC
